CN110431240A - 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 - Google Patents

在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 Download PDF

Info

Publication number
CN110431240A
CN110431240A CN201880018649.2A CN201880018649A CN110431240A CN 110431240 A CN110431240 A CN 110431240A CN 201880018649 A CN201880018649 A CN 201880018649A CN 110431240 A CN110431240 A CN 110431240A
Authority
CN
China
Prior art keywords
variant
antagonist
seq
ser
artificial sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880018649.2A
Other languages
English (en)
Chinese (zh)
Inventor
香农·布鲁斯
沙恩·麦卡锡
阿里斯·巴拉斯
弗雷德里克·杜威
奥姆里·戈特斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ray Jenner Pharmaceuticals
Original Assignee
Ray Jenner Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ray Jenner Pharmaceuticals filed Critical Ray Jenner Pharmaceuticals
Publication of CN110431240A publication Critical patent/CN110431240A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201880018649.2A 2017-04-13 2018-03-20 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 Pending CN110431240A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485077P 2017-04-13 2017-04-13
US62/485,077 2017-04-13
PCT/US2018/023266 WO2018190990A1 (en) 2017-04-13 2018-03-20 Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1

Publications (1)

Publication Number Publication Date
CN110431240A true CN110431240A (zh) 2019-11-08

Family

ID=61911717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880018649.2A Pending CN110431240A (zh) 2017-04-13 2018-03-20 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制

Country Status (11)

Country Link
US (2) US11708415B2 (enExample)
EP (3) EP3957752B1 (enExample)
JP (3) JP7321939B2 (enExample)
KR (2) KR102605045B1 (enExample)
CN (1) CN110431240A (enExample)
AU (3) AU2018252974B2 (enExample)
CA (1) CA3059350A1 (enExample)
IL (2) IL314591A (enExample)
MX (2) MX2019012171A (enExample)
SG (1) SG11201909457XA (enExample)
WO (1) WO2018190990A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3957752B1 (en) * 2017-04-13 2025-08-20 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
JP7165618B2 (ja) * 2019-04-23 2022-11-04 ジェネシスヘルスケア株式会社 アレルギー性鼻炎のリスクを判定する方法
EP3962515A1 (en) * 2019-05-01 2022-03-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
EP3999114A1 (en) 2019-07-16 2022-05-25 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
MX2024005769A (es) * 2021-11-11 2024-05-24 Regeneron Pharma Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33).

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1896275A (zh) * 2006-06-29 2007-01-17 四川大学华西医院 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒
CN101426518A (zh) * 2006-01-11 2009-05-06 艾罗文斯公司 用于治疗人类和非-人类灵长类中哮喘的方法和组合物
US20130253847A1 (en) * 2008-12-12 2013-09-26 Decode Genetics Ehf. Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
CN104531689A (zh) * 2014-12-12 2015-04-22 上海交通大学医学院附属新华医院 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用
US20150315262A1 (en) * 2012-12-10 2015-11-05 Vib Vzw Novel interleukin-33 inhibitors
US20160168640A1 (en) * 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
US20170096483A1 (en) * 2015-10-06 2017-04-06 Regeneron Pharmaceuticals, Inc. Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
MXPA02011682A (es) 2000-05-26 2003-05-14 Immunex Corp Uso de antagonistas de interleuquina-4 y composiciones de los mismos.
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
FR2900817B1 (fr) * 2006-05-12 2008-12-19 Gambro Lundia Ab Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2069403T3 (pl) 2006-10-02 2015-08-31 Regeneron Pharma Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) * 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
FI3088517T3 (fi) 2013-12-26 2023-11-30 Mitsubishi Tanabe Pharma Corp Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
NO2785538T3 (enExample) 2014-05-07 2018-08-04
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
JP6861630B2 (ja) * 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
SMT202100086T1 (it) 2015-03-31 2021-03-15 Medimmune Ltd Una nuova forma di il33, forme mutate di il33, anticorpi, saggi e metodi per usare gli stessi
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3957752B1 (en) * 2017-04-13 2025-08-20 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426518A (zh) * 2006-01-11 2009-05-06 艾罗文斯公司 用于治疗人类和非-人类灵长类中哮喘的方法和组合物
CN1896275A (zh) * 2006-06-29 2007-01-17 四川大学华西医院 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒
US20130253847A1 (en) * 2008-12-12 2013-09-26 Decode Genetics Ehf. Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
US20150315262A1 (en) * 2012-12-10 2015-11-05 Vib Vzw Novel interleukin-33 inhibitors
US20160168640A1 (en) * 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
CN104531689A (zh) * 2014-12-12 2015-04-22 上海交通大学医学院附属新华医院 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用
US20170096483A1 (en) * 2015-10-06 2017-04-06 Regeneron Pharmaceuticals, Inc. Biomarkers Related to Interleukin-33 (IL-33)-Mediated Diseases and Uses Thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASIF S TULAH等: "Defining the contribution of SNPs identified in asthma GWAS to clinical variables in asthmatic children", 《BMC MEDICAL GENETICS》 *
DEBORAH A MEYERS等: "The Genetics of Asthma: Towards a Personalised Approach to Diagnosis and Treatment", 《LANCET RESPIR MED》 *
N.EOMI S.GROTENBOER等: "Decoding asthma: Translating genetic variation in IL33 and IL1RL1 into disease pathophysiology", 《JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY》 *

Also Published As

Publication number Publication date
US20200031922A1 (en) 2020-01-30
AU2018252974B2 (en) 2024-10-17
EP3957752A2 (en) 2022-02-23
MX2024002689A (es) 2024-03-20
KR102751957B1 (ko) 2025-01-09
AU2024220214A1 (en) 2024-11-07
KR20190140928A (ko) 2019-12-20
US11708415B2 (en) 2023-07-25
KR102605045B1 (ko) 2023-11-27
RU2019136253A3 (enExample) 2021-12-17
EP4549586A3 (en) 2025-07-23
JP2023129607A (ja) 2023-09-14
JP7557581B2 (ja) 2024-09-27
MX2019012171A (es) 2019-11-25
IL314591A (en) 2024-09-01
IL269873B2 (en) 2025-01-01
EP3957752A3 (en) 2022-06-15
WO2018190990A1 (en) 2018-10-18
JP2020516289A (ja) 2020-06-11
IL269873B1 (en) 2024-09-01
JP2024163308A (ja) 2024-11-21
EP3610041A1 (en) 2020-02-19
KR20230164197A (ko) 2023-12-01
EP3957752B1 (en) 2025-08-20
CA3059350A1 (en) 2018-10-18
IL269873A (en) 2019-11-28
JP7321939B2 (ja) 2023-08-07
RU2019136253A (ru) 2021-05-13
EP4549586A2 (en) 2025-05-07
SG11201909457XA (en) 2019-11-28
AU2024220212A1 (en) 2024-11-07
AU2018252974A1 (en) 2019-11-28
US20230374145A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
KR102751957B1 (ko) Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
AU2017367691B2 (en) Methods of treating inflammatory conditions
AU2016333903B2 (en) Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
KR102103159B1 (ko) 항-ｉｌ-33 항체 및 이의 용도
KR102502640B1 (ko) Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
KR20190075133A (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
RU2776241C2 (ru) Лечение и ингибирование воспалительных заболеваний легких у пациентов с аллелями риска в генах, кодирующих il33 и il1rl1
TW202210511A (zh) 涉及il-18抗體之方法及治療
KR20110136253A (ko) 말론디알데히드에 의해 산화된 저밀도 지질단백질 및 카바밀레이트화된 저밀도 지질단백질에 특이적으로 결합하는 인간 단일클론 항체 및 그의 항원결합 단편
HK40069286A (en) Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination